Beijing Hotgen Biotech Co., Ltd. was founded in 2005 and is a national high-tech enterprise dedicated to the biopharmaceutical industry. The company was listed on the STAR Market of the Shanghai Stock Exchange in September 2019 (SSE Code: 688068).
Driven by continuous innovation in diagnostic technologies, Hotgen has established a portfolio of multi-omics diagnostic platforms covering protein biomarkers, glycan exosomes, DNA methylation, and other cutting-edge technologies. Its innovation incubation platform, the Future Technology Research Institute, is committed to translating frontier scientific discoveries into clinical applications, with strategic focus on nucleic acid therapeutics, antibody therapeutics, and healthcare innovations.
Among its groundbreaking achievements, SGC001, the world's first antibody therapeutic for emergency treatment of acute myocardial infarction (AMI), has received IND approvals from both China's NMPA and the U.S. FDA, as well as FDA Fast Track Designation, and has entered Phase II clinical trials.
Guided by its mission of "Developing Biotechnology, Benefiting Human Health," Hotgen is committed to building a fully integrated industrial ecosystem spanning innovative diagnostics to novel therapeutics, delivering advanced healthcare solutions that improve lives worldwide.
